BYETTA PACKAGE INSERT PDF
Patient Information Leaflet. Package leaflet: Information for the patient. Byetta 5 micrograms solution for injection in pre-filled pen. Byetta 10 micrograms solution . Learn about BYETTA, the BYETTA Pen. in patients with prior severe hypersensitivity reactions to exenatide or to any of the product components. PRODUCT MONOGRAPH. BYETTA® exenatide injection. µg/mL. mL prefilled pen (60 doses of 5 µg/dose) and. mL prefilled pen.
|Published (Last):||27 March 2017|
|PDF File Size:||14.89 Mb|
|ePub File Size:||14.9 Mb|
|Price:||Free* [*Free Regsitration Required]|
Moderate Disturbances of blood glucose, including hyperglycemia and hypoglycemia, have been reported in patients treated concomitantly with quinolones and an antidiabetic agent. Exenatide is a amino acid GLP-1 agonist isolated from the salivary gland venom of the lizard Heloderma suspectum Gila monster.
Higher incidences were noted in males above controls in all treated groups at 2 times or more clinical exposure.
Type 2 Diabetes Medication | BYETTA® (exenatide) injection
Because of this, a potential pharmacodynamic interaction exists between these drugs and all antidiabetic agents, including incretin mimetics. Exenatide acts to improve glucose control via several mechanisms.
Patients who are taking antidiabetic agents should monitor for worsening glycemic control when a phenothiazine is instituted. Based on animal data, advise pregnant women of the potential risk to a fetus.
Monitor for changes in INR and bleeding when these drugs are coadministered. Monitor patients on antidiabetic therapy for blood glucose control if niacin nicotinic acid is added or deleted to the medication regimen and adjust dosages as clinically warranted Nicotine: Ethinyl Estradiol; Norethindrone; Ferrous fumarate: Taking an oral contraceptive at least 1 hour before an incretin mimetic injection should reduce the risk of an effect on contraceptive or hormonal absorption.
One study stated that additional garlic supplementation 0. Moderate In patients with diabetes mellitus, fluoxetine may alter glycemic control.
Moderate Disopyramide may enhance the hypoglycemic effects of antidiabetic agents. The clinical effects of these competing mechanisms is not known. Use in pediatric patients is not recommended as safety and effectiveness have not been established. The mechanism of this interaction is not available although it pacakge be due to delayed gastric emptying from exenatide use and the clinical impact has not been assessed.
Moderate Monitor blood glucose levels regularly in patients with diabetes, especially when lanreotide treatment is initiated or when the dose is altered. Altered renal function was reversible in many cases with supportive treatment and discontinuation of potentially causative agents, including exenatide. Let the autoinjector come to room temperature for approximately 15 minutes before administration.
Moderate Sympathomimetic agents and adrenergic agonists tend to increase blood glucose concentrations when administered systemically. The clinical effects of these competing mechanisms are not known. In Type 2 diabetes patients with partially intact insulin reserves, octreotide administration may result in decreases in plasma insulin paackage and hyperglycemia.
Administer twice daily, within the minute time period prior to the morning and evening meals.
inser Unlock the autoinjector by turning the knob from lock to unlock until a click is heard. Postmarketing reports of increased international normalized ratio INR sometimes associated with bleeding with concomitant use of warfarin.
Do not administer by intravenous or intramuscular injection. If pancreatitis is suspected, BYETTA should be discontinued promptly and should not be restarted if pancreatitis is confirmed.
Byetta (exenatide) dose, indications, adverse effects, interactions from
Push the autoinjector against the skin at the chosen injection site. Moderate Niacin nicotinic acid interferes with glucose metabolism and can result in hyperglycemia.
It may be necessary to adjust the dose of antidiabetic agents if thyroid hormones are added or discontinued. Hyperglycemia has developed in patients with diabetes mellitus following discontinuation of the drug. Adequate blood glucose packaeg should be continued and followed. Patients receiving incretin mimetics should be closely monitored for signs indicating loss of diabetic control when therapy with a hydantoin is instituted.
Diuretic-induced hypokalemia may also lead to hyperglycemia. For patients who are to self-administering exenatide, adequate oral as well as written instructions on the use of the injector pen should be supplied before they self-administer a dose. Moderate Insedt, including symptomatic episodes, has been noted in post-marketing reports with linezolid in patients with diabetes mellitus receiving therapy with antidiabetic agents, such inserr insulin and oral hypoglycemic agents.
Recommendations will be communicated once the review is complete; continue to consider precautions related to pancreatic risk until more data are available. Ethinyl Estradiol; Norethindrone Acetate; Ferrous fumarate: Artsana InsuPen 29G and 31G pen needles.